Mechanisms of action and resistance in histone methylation-targeted therapy (IMAGE)

University of Tokyo

Mechanisms of action and resistance in histone methylation-targeted therapy

Caption

Valemetostat reduces methylated histone levels by inhibiting EZH1/2 and induces expression of tumor suppressor genes, resulting in a sustained clinical benefit. In some patients receiving long-term therapy, mutations in target molecules or aberrant DNA methylation can cause chromatin structure reaggregation, leading to clinical relapse.

Credit

2024 Makoto Yamagishi, The University of Tokyo

Usage Restrictions

News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.